North America Women'S Health Market Size & Outlook
Global Market
Related Markets
North America women's health market highlights
- The North America women's health market generated a revenue of USD 22,965.7 million in 2025.
- The market is expected to grow at a CAGR of 2.9% from 2026 to 2033.
- In terms of segment, contraceptives was the largest revenue generating application in 2025.
- Menopause is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 22,965.7 million |
| Market revenue in 2033 | USD 29,728.5 million |
| Growth rate | 2.9% (CAGR from 2026 to 2033) |
| Largest segment | Contraceptives |
| Fastest growing segment | Menopause |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, North America region accounted for 42.9% of the global women's health market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 20,294.6 million by 2033.
Increase in the population of older women in the region is one of the key factors driving the demand for women’s health products in North America. More than 15% of the women in North America are above the age of 65 years.
Moreover, increasing prevalence of osteoporosis in postmenopausal women is a key factor expected to drive the demand for women’s health products, including drugs and devices. Increase in the number of market approvals of women’s health drugs and high healthcare expenditure are among the factors contributing to market growth.
For instance, in May 2023, the U.S. FDA approved Veozah (fezolinetant) to reduce the frequency and severity of hot flashes in menopause. Moreover, in May 2020, AbbVie’s Oriahnn received FDA approval. It is an oral medication indicated for heavy menstrual bleeding due to uterine fibroids.
No credit card required*
Publish Date: Feb 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Women's Health Market Scope
Women's Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Ferring | View profile | 5001-10000 | Saint-prex, Vaud, Switzerland, Europe | www.ferring.com |
| Agile Therapeutics Inc | View profile | 19 | 500 College Road East, Suite 310, Princeton, NJ, United States, 08540 | www.agiletherapeutics.com |
| Blairex Laboratories | View profile | 101-250 | Columbus, Indiana, United States, North America | www.blairex.com |
| Apothecus | View profile | 11-50 | Hicksville, New York, United States, North America | apothecus.com |
North America Women's Health Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Women's Health Market Outlook will help companies and investors design strategic landscapes.
Contraceptives was the largest segment with a revenue share of 29.51% in 2025.
Horizon Databook has segmented the North America women's health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2021 to 2033.
Increase in the population of older women in the region is one of the key factors driving the demand for women’s health products in North America. More than 15% of the women in North America are above the age of 65 years.
Moreover, increasing prevalence of osteoporosis in postmenopausal women is a key factor expected to drive the demand for women’s health products, including drugs and devices. Increase in the number of market approvals of women’s health drugs and high healthcare expenditure are among the factors contributing to market growth.
For instance, in May 2023, the U.S. FDA approved Veozah (fezolinetant) to reduce the frequency and severity of hot flashes in menopause. Moreover, in May 2020, AbbVie’s Oriahnn received FDA approval. It is an oral medication indicated for heavy menstrual bleeding due to uterine fibroids.
- North America Women'S Health Market Application Outlook (Revenue, USD Million , 2021-2033)
- Hormonal Infertility
- Contraceptives
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Polycystic Ovary Syndrome (PCOS)
- North America Women'S Health Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Hormonal Therapies
- Bone Health Agents
- Fertility Agents
- GnRH Modulators
- Pain and Symptom Management
- Metabolic Agents
- Others Drug Class
- North America Women'S Health Market Age Outlook (Revenue, USD Million , 2021-2033)
- 50 years and above
- Others Age
Reasons to subscribe to Women's Health Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Women's Health Market Outlook databook
- Our clientele includes a mix of Women's Health Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Women's Health Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Women's Health Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Women'S Health Market, 2021-2033 (US$M)
North America women's health market statistics, by application, 2021-2033 (US$M)
